|
| 36689214 | Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial. | JAMA Neurol | 2023 |
| 37905526 | Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study. | | 2023 |
| 37978852 | Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study. | | 2023 |
| 36619856 | Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies. | | 2023 |
| 35196927 | The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. | Mult Scler | 2022 |
| 35765217 | Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5â¿¿years of follow-up in the DAYBREAK open-label extension trial. | Multiple Sclerosis Journal | 2022 |
| 36001711 | Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. | N Engl J Med | 2022 |
| 36000489 | Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations. | Multiple Sclerosis Journal | 2022 |
| 35674070 | Fluid phase biomarkers in multiple sclerosis. | Current Opinion in Neurology | 2022 |
| 35720271 | Impact of Diminished Expression of circRNA on Multiple Sclerosis Pathomechanisms. | Frontiers in Immunology | 2022 |
| 36188381 | Optical coherence tomography assessment of axonal and neuronal damage of the retina in patients with familial and sporadic multiple sclerosis. | Frontiers in Neurology | 2022 |
| 34240656 | Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. | Mult Scler | 2022 |
| 33764197 | Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey. | Mult Scler | 2022 |
| 35158476 | Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis. | Multiple Sclerosis and Related Disorders | 2022 |
| 34418402 | Myelin-oligodendrocyte glycoprotein antibody-associated disease. | Lancet Neurol | 2021 |
| 33592384 | Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals. | Multiple Sclerosis and Related Disorders | 2021 |
| 33892317 | Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. | Multiple Sclerosis and Related Disorders | 2021 |
| 33666121 | Hemophagocytic lymphohistiocytosis associated with ocrelizumab treatment in a patient with multiple sclerosis. | Multiple Sclerosis Journal | 2021 |
| 34035833 | Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. | Therapeutic Advances in Neurological Disorders | 2021 |
| 34925876 | Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study. | Multiple Sclerosis Journal - Experimental, Translational and Clinical | 2021 |
| 34385287 | Multiple Sclerosis: circRNA Profile Defined Reveals Links to B-Cell Function. | Neurology: Neuroimmunology and NeuroInflammation | 2021 |
| 30785358 | Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management. | Multiple Sclerosis Journal | 2020 |
| 32316658 | The Heat Shock Protein HSP70 Promotes Th17 Genes' Expression via Specific Regulation of microRNA. | International Journal of Molecular Sciences | 2020 |
| 31953790 | Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study. | CNS Drugs | 2020 |
| 31835206 | Impact of informative censoring on the treatment effect estimate of disability worsening in multiple sclerosis clinical trials. | Multiple Sclerosis and Related Disorders | 2020 |
| 32451615 | Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. | Journal of Neurology | 2020 |
| 32757523 | Ofatumumab versus Teriflunomide in Multiple Sclerosis. | N Engl J Med | 2020 |
| 33085075 | Recommendations of the Polish Medical Society of Radiology and the Polish Society of Neurology for a protocol concerning routinely used magnetic resonance imaging in patients with multiple sclerosis. | Neurologia i Neurochirurgia Polska | 2020 |
| 33335562 | Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease. | Therapeutic Advances in Neurological Disorders | 2020 |
| 32612727 | Recommendations of the Polish Medical Society of Radiology and the Polish Society of Neurology for the routinely used magnetic resonance imaging protocol in patients with multiple sclerosis. | Polish Journal of Radiology | 2020 |
| 31163273 | Circular RNAs as a novel layer of regulatory mechanism in multiple sclerosis. | Journal of Neuroimmunology | 2019 |
| 31664710 | Novel emerging treatments for NMOSD. | Neurologia i Neurochirurgia Polska | 2019 |
| 30289355 | Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. | Multiple Sclerosis Journal | 2019 |
| 30043658 | Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. | Multiple Sclerosis Journal | 2019 |
| 31492651 | Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. | Lancet Neurology, The | 2019 |
| 31492652 | Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. | Lancet Neurology, The | 2019 |
| 28273783 | Multiple sclerosis: Serum-derived exosomes express myelin proteins. | Multiple Sclerosis Journal | 2018 |
| 28984179 | Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE. | Multiple Sclerosis Journal | 2018 |
| 30547103 | Follow-on glatiramer acetate. | eNeurologicalSci | 2018 |
| 29568544 | No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. | Multiple Sclerosis Journal - Experimental, Translational and Clinical | 2018 |
| 29353550 | ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. | Mult Scler | 2018 |
| 29352526 | ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. | Eur J Neurol | 2018 |
| 28090798 | Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results. | Multiple Sclerosis Journal | 2017 |
| 28643586 | New insights into the burden and costs of multiple sclerosis in Europe: Results for Poland. | Multiple Sclerosis Journal | 2017 |
| 28385180 | The role of exosomes in CNS inflammation and their involvement in multiple sclerosis. | Journal of Neuroimmunology | 2017 |
| 28803660 | Multiple sclerosis: Skin-induced antigen-specific immune tolerance. | Journal of Neuroimmunology | 2017 |
| 28411393 | Global exosome transcriptome profiling reveals biomarkers for multiple sclerosis. | Annals of Neurology | 2017 |
| 28835403 | Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. | Neurology | 2017 |
| 28835401 | Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. | Neurology | 2017 |
| 28480981 | Multiple sclerosis: Presence of serum antibodies to lipids and predominance of cholesterol recognition. | Journal of Neuroscience Research | 2017 |